BioInnovation Institute (BII), life science incubator, has announced the addition of six companies who will receive additional financial support through its Venture House programme, created to further support former Venture Lab companies through their next phase of growth. Three of these are key to the advancement of gene therapies, cancer research and Parkinson’s treatments. 

The new companies include: 

  • Amplify Therapeutics, developing novel, disease-modifying treatments for lysosomal Parkinson’s disease 
  • Fuse Vectors, developing a novel platform to manufacture viral vector-based gene therapies, which hold the promise to cure genetic illnesses through single-dose treatments 
  • Metsystem, determining whether and where cancer will metastasise, and which drugs will most effectively combat it 

The programme consists of four sprints, each focused on a key development area to help mature the project and ultimately attract further funding. The first sprint focuses on helping companies develop an operational plan, while the following sprints provide training and support in fundraising, partnership, and leadership.  

Since its inception in 2018, BII has supported 100 start-ups and projects with €97 million alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level. In total, BII’s start-ups have raised over €428 million in external funding from both local and international investors.   

Recent company successes include Embark Laboratories, Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.  

Megan Thomas, Multimedia Editor, DDW